Last reviewed · How we verify
Administration of ceralasertib and durvalumab
Administration of ceralasertib and durvalumab is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.
At a glance
| Generic name | Administration of ceralasertib and durvalumab |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (PHASE1)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (PHASE1, PHASE2)
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (PHASE2)
- Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (PHASE2)
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (PHASE2)
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (PHASE2)
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of ceralasertib and durvalumab CI brief — competitive landscape report
- Administration of ceralasertib and durvalumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Administration of ceralasertib and durvalumab
What is Administration of ceralasertib and durvalumab?
Administration of ceralasertib and durvalumab is a Small molecule drug developed by AstraZeneca.
Who makes Administration of ceralasertib and durvalumab?
Administration of ceralasertib and durvalumab is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What development phase is Administration of ceralasertib and durvalumab in?
Administration of ceralasertib and durvalumab is in Phase 1.